HanchorBio's HCB101 Receives Significant FDA Orphan Drug Designation for Gastric Cancer Treatment

HanchorBio Achieves Milestone in Gastric Cancer Treatment

HanchorBio, Inc., a biotechnology company known for its innovative immunotherapy solutions, has made headlines with the recent announcement of the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its lead candidate, HCB101, for the treatment of gastric cancer. This landmark achievement underscores HanchorBio's commitment to tackling areas of high unmet medical need, particularly in oncology.

Understanding Orphan Drug Designation

The Orphan Drug Designation is a significant designation granted by the FDA aimed at encouraging the development of treatments for rare diseases affecting fewer than 200,000 patients in the United States. In the case of gastric cancer, despite being known as a severe and often lethal disease, the prevalence in the U.S. is relatively low, making HCB101's designation quite meaningful. The designation not only validates HanchorBio's strategic direction but also provides critical regulatory support to further its clinical development.

What Is HCB101?

HCB101 is a cutting-edge CD47-SIRPα pathway inhibitor, developed uniquely as an affinity-optimized and toxicity-mitigated SIRPα-IgG4 Fc fusion protein. Its design is engineered to restore macrophage-mediated phagocytosis and improve antigen presentation—key functions in the immune response against cancer, while minimizing the hematologic toxicities often associated with earlier CD47-targeting therapies. This innovative approach enables HCB101 to potentially combine with established treatments, enhancing overall therapeutic efficacy for patients.

Milestones and Ongoing Trials

Dr. Scott Liu, the Founder and CEO of HanchorBio, expressed enthusiasm about the milestone, stating that receiving the FDA's Orphan Drug Designation emphasizes not only the company's scientific endeavor but also its deep-rooted commitment to patients facing gastric cancer, a disease with dire prospects even with advancements in treatment modalities.

Currently, HCB101 is being assessed across various clinical studies, including a Phase 1b/2a trial (NCT06771622) that analyses its efficacy in combination with ramucirumab and paclitaxel, particularly in advanced gastric cancer settings. Preliminary results suggest that HCB101 shows promise in delivering anti-tumor activity, all while maintaining a safety profile that aligns with the drug's innovative design.

The Importance of This Development

The designation of HCB101 as an orphan drug not only signifies the critical need for advancements in gastric cancer treatment but also provides HanchorBio with development incentives such as tax credits for qualified clinical trial expenses and a potential exclusivity period for seven years upon approval. Such support is crucial for firms like HanchorBio, which are dedicated to pushing the boundaries of cancer therapies through innovation.

Moreover, Alvin Luk, President and Chief Medical Officer of HanchorBio, highlighted that the FDA's acknowledgment reflects the seriousness of gastric cancer in the clinical landscape. The design of HCB101, tailored for repeated dosing while being an integral part of combination strategies, represents a pivotal advancement against solid tumors, especially in second-line treatment scenarios where current standards often fall short.

A Future Focused on Patient Needs

Looking ahead, HanchorBio intends to progress HCB101 through extensive global clinical development while investigating its potential as a foundational immunotherapy across various solid tumor indications. The company's aspirations to forge partnerships and explore licensing opportunities emphasize its strategic approach to accelerating the development of this promising therapy.

Given the challenges associated with gastric cancer treatments, the establishment of HCB101 as a reliable option represents hope for many patients battling this formidable disease. HanchorBio continues to spearhead innovation in cancer therapies, with the aim of ultimately enhancing the quality of life for patients worldwide.

To learn more about HanchorBio and its innovative treatments, visit HanchorBio.com.